GlassScriptPhysician profile
Alexander Ostrovsky
NPI 1548310238
$9,479.29
in general payments reported to CMS, 2019-2025
66 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $183 · 2021: $660 · 2022: $1,814 · 2023: $1,886 · 2024: $2,155 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,696 · Education: $70.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,695.64 |
| Education | $70.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $673.48 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $660.19 | 2019-2025 | Erleada, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $620.46 | 2019-2025 | |
| Abbvie INC. | $517.59 | 2019-2025 | |
| Genentech USA, INC. | $443.63 | 2019-2025 | Polivy, Venclexta, Phesgo |
| Daiichi Sankyo INC. | $424.47 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Astellas Pharma US INC | $399.69 | 2019-2025 | Xtandi, Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $389.08 | 2019-2025 | Opdualag, Opdivo, Augtyro |
| Incyte Corporation | $373.02 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $344.97 | 2019-2025 | Lynparza, Enhertu |
| Eisai INC. | $287.38 | 2019-2025 | |
| Pfizer INC. | $272.49 | 2019-2025 | |
| Amgen INC. | $265.56 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
| Celgene Corporation | $218.26 | 2022-2025 | Reblozyl, Pomalyst |
| Glaxosmithkline, LLC. | $213.57 | 2021-2025 | Jemperli, Zejula, Ojjaara |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $212.33 | 2019-2025 | |
| Stemline Therapeutics INC. | $206.73 | 2023-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $186.04 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $180.43 | 2021-2025 | Trodelvy |
| Seagen INC. | $167.56 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $161.39 | 2020-2024 | |
| Kite Pharma, INC. | $157.07 | 2022-2025 | Yescarta |
| Beone Medicines USA, INC. | $124.73 | 2025 | Brukinsa, Tevimbra |
| Acrotech Biopharma INC. | $121.42 | 2021-2024 | Beleodaq |
| Takeda Pharmaceuticals U.S.A., INC. | $105.88 | 2022-2025 | Ninlaro |
| Lilly USA, LLC | $101.57 | 2019-2024 | Verzenio |
| Tersera Therapeutics LLC | $100.97 | 2019-2023 | Zoladex |
| Mirati Therapeutics, INC. | $94.75 | 2023-2024 | Krazati |
| Array Biopharma INC | $85.67 | 2021-2024 | Mektovi, Braftovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $85.20 | 2019-2024 | |
| Emd Serono, INC. | $81.69 | 2021-2025 | Tepmetko |
| Puma Biotechnology, INC. | $78.98 | 2021-2024 | Nerlynx |
| Apellis Pharmaceuticals, INC. | $69.75 | 2023-2024 | Empaveli |
| Janssen Pharmaceuticals, INC | $66.09 | 2019-2022 | |
| Myovant Sciences INC. | $57.40 | 2021-2022 | |
| Sobi, INC | $56.91 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $49.95 | 2022-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $49.23 | 2019-2024 | Tavalisse, Rezlidhia |
| Foundation Medicine, INC. | $48.52 | 2023 | |
| Alexion Pharmaceuticals, INC. | $48.37 | 2023-2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $48.09 | 2019-2023 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $46.65 | 2023-2025 | Somatuline Depot, Onivyde |
| Mylan Institutional INC. | $46.45 | 2022-2023 | Ogivri, Fulphila |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.44 | 2023 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $41.84 | 2022-2023 | Yonsa, Odomzo |
| Tesaro, INC. | $41.24 | 2019 | |
| Recordati_rare_diseases_inc. | $37.99 | 2024 | Sylvant |
| Karyopharm Therapeutics INC. | $31.85 | 2024 | Xpovio |
| Deciphera Pharmaceuticals INC. | $31.61 | 2021-2025 | Tgct, Qinlock |
| Exelixis INC. | $31.19 | 2021-2023 | Cabometyx |
| G1 Therapeutics, INC. | $23.18 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $21.93 | 2023 | Orgovyx |
| Csl Behring | $21.31 | 2024 | Hizentra |
| Morphosys, US INC. | $20.41 | 2022 | |
| Beigene USA, INC. | $19.28 | 2024 | Brukinsa |
| Helsinn Therapeutics (U.S.), INC. | $19.08 | 2019 | |
| Heron Therapeutics, INC. | $18.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.16 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.79 | 2022 | |
| Servier Pharmaceuticals LLC | $15.71 | 2024 | |
| Secura Bio, INC. | $15.02 | 2024 | Copiktra |
| Spectrum Pharmaceuticals INC. | $14.85 | 2025 | Rolvedon |
| Fortovia Therapeutics, INC. | $14.55 | 2020 | |
| Adc Therapeutics America, INC. | $14.08 | 2024 | |
| Dova Pharmaceuticals | $13.82 | 2019 | |
| Taiho Oncology, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ostrovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.